Scholar Rock Holding Co. (NASDAQ:SRRK) Stock Position Reduced by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP trimmed its position in Scholar Rock Holding Co. (NASDAQ:SRRK) by 41.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 91,230 shares of the company’s stock after selling 65,611 shares during the quarter. ExodusPoint Capital Management LP owned approximately 0.10% of Scholar Rock worth $3,943,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in shares of Scholar Rock by 51.8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock worth $34,000 after buying an additional 269 shares during the last quarter. Quarry LP boosted its stake in Scholar Rock by 3,443.3% in the third quarter. Quarry LP now owns 4,500 shares of the company’s stock valued at $36,000 after acquiring an additional 4,373 shares during the period. Global Retirement Partners LLC raised its position in shares of Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock worth $39,000 after purchasing an additional 766 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock worth $48,000 after purchasing an additional 1,031 shares during the last quarter. Finally, Amalgamated Bank boosted its position in Scholar Rock by 30.6% during the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock valued at $114,000 after purchasing an additional 620 shares during the period. 91.08% of the stock is currently owned by institutional investors.

Insider Activity at Scholar Rock

In related news, insider Tracey Sacco sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $33.08, for a total transaction of $215,020.00. Following the transaction, the insider now owns 71,750 shares in the company, valued at $2,373,490. This trade represents a 8.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Katie Peng sold 1,006 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $34.42, for a total value of $34,626.52. Following the completion of the sale, the director now owns 30,319 shares of the company’s stock, valued at $1,043,579.98. This trade represents a 3.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 299,772 shares of company stock worth $11,245,798 in the last 90 days. Corporate insiders own 19.20% of the company’s stock.

Scholar Rock Trading Down 12.4 %

NASDAQ:SRRK opened at $26.90 on Monday. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98. The business has a fifty day moving average of $36.31 and a 200-day moving average of $34.01. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of -11.45 and a beta of 0.56.

Wall Street Analysts Forecast Growth

Separately, Wedbush reiterated an “outperform” rating and issued a $50.00 target price on shares of Scholar Rock in a research note on Tuesday, March 25th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Scholar Rock presently has an average rating of “Buy” and a consensus target price of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.